1. The subject of this order is the successive supply of medicines to the National Institute of Oncology named after Maria Skłodowsk-Curie - the State Research Institute of the Department of Gliwice.

2. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.1÷2.21 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

3. The item of the order is divided into 21 separate tasks.

4. Information clause arising from the contents of Article 13 of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of individuals in connection with the processing of personal data and on the free movement of such data and repealing Directive 95/46/EC, The Ordering Authority posted in SWZ.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.1 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.10 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.11 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.12 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

11. A condition for participation in the public contract award procedure is to bring a defect of PLN 21 923,00. Details of the defect are contained in Chapter XI of SWZ.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.13 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.14 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.15 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.16 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.17 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.18 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.19 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.2 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.20 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

11. A condition for participation in the public procurement procedure is to bring a defect of PLN 28 350,00. Details of the defect are contained in Chapter XI of SWZ.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.21 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.3 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.4 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex 2.5 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

11. A condition for participation in the public procurement procedure is to bring a defect of PLN 73 922,00. Details of the defect are contained in Chapter XI of SWZ.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.6 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

11. A condition for participation in the public procurement procedure is to lodge a defect of PLN 147 643,00. Details of the defect are contained in Chapter XI of SWZ.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.7 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.8 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.

11. A condition for participation in the public procurement procedure is to bring a defect of: 82 778,00 PLN. Details of the defect are contained in Chapter XI of SWZ.

1. The description of the object of the contract and the conditions for the execution of the order are contained in

— “Assortment and Price Specification” - Annex No 2.9 to SWZ,

— “Designed provisions of the contract to be entered into the content of the contract” - Annex 4 to SWZ.

2. Medicinal products constituting the subject of the contract must be authorised for use in Poland in accordance with the provisions of the Pharmaceutical Law Act of 6 September 2001 (i.e. Journal of Laws of 2021, item 974, as amended) - the Contractor should have any legal documents required authorising the market in the Republic of Poland for the medicinal product offered and present it at the request of the Ordering Party (not applicable to medicines from the target import).

3. The medicinal products subject to this order have established quality standards. These standards have been established for each medicinal product during its registration and are the same within the chemical substances included in their composition. Medicinal products for their use do not require any distinguishing elements of their components within individual substances. In addition, any medicinal product traded on the territory of the Republic of Poland must be registered.

4. The Contracting Authority allows the possibility of changing oral forms except for soluble forms and the possibility of changing the ampoule to a vial.

5. Preparations with the same chemical name, but with different doses, must be offered from one manufacturer so that in practice there is a possibility of combining doses. This refers to medicinal products occurring in the same form and applies to substances in the list of substances used in the therapeutic programmes and substances used in chemotherapy, and applies only to oral and injectable forms. At the same time, the Ordering Party informs that the above notation does not apply to combining oral forms with injections (we do not combine such forms with each other). Consequently, Contractors may offer medicinal products to various manufacturers.

6. In tasks where no dose size is given, the Ordering Party reserves the possibility of placing orders for all doses produced by the manufacturer concerned.

7. If the medicinal product in the international name is on the refund leaf, the medicinal product offered must be on it and its price must be equal to or below the funding limits.

8. The medicinal products offered must have at least 12 months of expiry from the date of delivery. The Contracting Authority shall allow delivery of the item of the order with a shelf life of less than 12 months only if the Contractor has obtained the Contracting Authority's written consent.

9. The Contracting Authority does not provide for the conclusion of a framework agreement, the establishment of a dynamic purchasing system, electronic auctions and supplementary orders.

10. A deadline for submission of tenders has been set 5 days shorter (30 days) than referred to in Article 138 (1) (35 days), pursuant to Article 138 (4) of the Pzp Act, according to which “The Contracting Authority may set a deadline for submission of tenders 5 days less than those specified in paragraph 1 if the submission of tenders is carried out in full by means of electronic communication, as referred to in Article 63 (1). ' In the scope of this post-step, the submission of tenders shall be carried out entirely by means of electronic communication, as set out in Article 63 (1) of the Law Pzp.